​Cambridge’s Aveo eyes turnaround as cancer drug nears E.U. nod

Aveo Oncology fell out of favor with investors in 2013 after the FDA rejected its kidney cancer drug, tivozanib. Then, last year, the U.S. Securities and Exchange Commission sued three of Aveo 's former top executives— and reached a $4 million settlement with the Cambridge biotech — over allegations that it fraudulently concealed the FDA's concerns about the drug from investors. After all that, on Friday, Aveo (Nasdaq: AVEO) got a dose of good news, announcing that an E.U. scient ific committee… (Source: bizjournals.com Health Care:Biotechnology headlines)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2s03I3G
via IFTTT